Advertisement
YOU ARE HERE: LAT HomeCollectionsSicor Inc
IN THE NEWS

Sicor Inc

FEATURED ARTICLES
BUSINESS
November 4, 2000
The Irvine specialty pharmaceuticals company posted third-quarter net income of $8.4 million, or 8 cents a share, up from $3 million, or 3 cents a share, for the prior-year period. Revenue rose 29% to $71.7 million.
ARTICLES BY DATE
BUSINESS
October 18, 2001 | A Times Staff Writer
Sicor Inc. said it netted $203 million from a secondary stock offering. The Irvine generic-drug maker offered 23 million shares priced at $18.50 a share, but 11.5 million shares were sold by an affiliate of Chief Executive Carlo Salvi. Sicor said it plans to use proceeds for general corporate purposes, including working capital, capital expenditures and acquisitions. The stock closed Wednesday at $19.11, off 79 cents a share, in Nasdaq trading.
Advertisement
BUSINESS
November 2, 1999
Irvine pharmaceutical company Sicor Inc. said it earned $3.1 million, or 4 cents a share, for the third quarter, contrasted with a net loss of $3.3 million, or 4 cents a share, for the comparable quarter last year. Revenue increased 27% to $55.4 million.
BUSINESS
April 27, 2001
The Irvine pharmaceutical company reported that net income for the first quarter rose to $11.9 million, or 11 cents a share, from $3.6 million, or 4 cents a share, for the first quarter of 2000. A pretax charge of $3.5 million was recorded in the first quarter of 2001 related to the impairment of certain assets associated with the company's Italian operations. In the first quarter of 2000, a special charge of $2.9 million related to an accounting change was recorded.
BUSINESS
August 27, 1999 | (Bloomberg News)
Sicor Inc. said Thursday that it has resolved Food and Drug Administration officials' concerns over problems at a company facility in Irvine. Sicor's Gensia Sicor Pharmaceuticals Inc. unit said in July that it had received a warning letter asking it to improve its record keeping concerning the cleaning of tanks used to mix drugs and to improve its procedures for backing up computer information.
BUSINESS
November 20, 1999 | (Dow Jones)
Sicor Inc., an Irvine maker of injectable drugs, has registered to offer more than 9.5 million common shares on behalf of five selling stockholders, according to a shelf registration filed with the Securities and Exchange Commission. The offer included 867,500 shares that can be issued upon exercise of warrants to investors at $5.75 per share. The proposed maximum offering price is $4.59 a share. The primary selling stockholders are Stamford Investments Ltd., with 5.
BUSINESS
February 23, 2001 | Times Staff and Wire Reports
Sicor Inc. posted hefty increases in earnings and revenue for the fourth quarter and year, and predicted strong gains for 2001. The Irvine pharmaceutical company said fourth-quarter net income more than doubled to $9.8 million, or 9 cents a share, from $4 million, or 5 cents a share, a year earlier. Revenue increased 24% to $81 million. Net income for the year climbed to $30 million, or 29 cents a share, from $5.7 million, or 7 cents a share, for 1999. Revenue rose 28% to $293.8 million.
BUSINESS
October 18, 2001 | A Times Staff Writer
Sicor Inc. said it netted $203 million from a secondary stock offering. The Irvine generic-drug maker offered 23 million shares priced at $18.50 a share, but 11.5 million shares were sold by an affiliate of Chief Executive Carlo Salvi. Sicor said it plans to use proceeds for general corporate purposes, including working capital, capital expenditures and acquisitions. The stock closed Wednesday at $19.11, off 79 cents a share, in Nasdaq trading.
BUSINESS
April 23, 1998 | BARBARA MARSH, TIMES STAFF WRITER
Gensia Sicor Inc., a once-high-flying biotech firm that crashed, has embarked on a more modest mission. The company, which failed to develop its own new drug for heart patients, has merged with another firm, moved its headquarters to Irvine from San Diego and opened a new plant to manufacture both experimental and commercial drugs for other companies.
BUSINESS
February 23, 2001 | Times Staff and Wire Reports
Sicor Inc. posted hefty increases in earnings and revenue for the fourth quarter and year, and predicted strong gains for 2001. The Irvine pharmaceutical company said fourth-quarter net income more than doubled to $9.8 million, or 9 cents a share, from $4 million, or 5 cents a share, a year earlier. Revenue increased 24% to $81 million. Net income for the year climbed to $30 million, or 29 cents a share, from $5.7 million, or 7 cents a share, for 1999. Revenue rose 28% to $293.8 million.
BUSINESS
November 20, 1999 | (Dow Jones)
Sicor Inc., an Irvine maker of injectable drugs, has registered to offer more than 9.5 million common shares on behalf of five selling stockholders, according to a shelf registration filed with the Securities and Exchange Commission. The offer included 867,500 shares that can be issued upon exercise of warrants to investors at $5.75 per share. The proposed maximum offering price is $4.59 a share. The primary selling stockholders are Stamford Investments Ltd., with 5.
BUSINESS
November 2, 1999
Irvine pharmaceutical company Sicor Inc. said it earned $3.1 million, or 4 cents a share, for the third quarter, contrasted with a net loss of $3.3 million, or 4 cents a share, for the comparable quarter last year. Revenue increased 27% to $55.4 million.
BUSINESS
August 27, 1999 | (Bloomberg News)
Sicor Inc. said Thursday that it has resolved Food and Drug Administration officials' concerns over problems at a company facility in Irvine. Sicor's Gensia Sicor Pharmaceuticals Inc. unit said in July that it had received a warning letter asking it to improve its record keeping concerning the cleaning of tanks used to mix drugs and to improve its procedures for backing up computer information.
BUSINESS
April 23, 1998 | BARBARA MARSH, TIMES STAFF WRITER
Gensia Sicor Inc., a once-high-flying biotech firm that crashed, has embarked on a more modest mission. The company, which failed to develop its own new drug for heart patients, has merged with another firm, moved its headquarters to Irvine from San Diego and opened a new plant to manufacture both experimental and commercial drugs for other companies.
Los Angeles Times Articles
|